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Using immunofluorescence and neutralization assays,
we detected antibodies to human severe acute respiratory
syndrome–associated coronavirus (SARS-CoV) and/or ani-
mal SARS-CoV–like virus in 17 (1.8%) of 938 adults recruit-
ed in 2001. This finding suggests that a small proportion of
healthy persons in Hong Kong had been exposed to SARS-
related viruses at least 2 years before the recent SARS out-
break. 
A
novel coronavirus has been identified as the cause of
the 2003 global outbreak of severe acute respiratory
syndrome (SARS) (1–5). Genetic analysis and epidemio-
logic studies suggest that SARS coronavirus (CoV) was
introduced into humans not long ago. Recently, SARS-
CoV–like viruses were isolated in Himalayan palm civets
and racoon dogs in a retail live animal market in
Guangdong Province, southern China (6), and some of the
animals tested had antibodies to SARS-CoV–like virus.
Phylogenetic analysis showed that the SARS-CoV–like
animal viruses were closely related to the viruses found in
humans. Serologic surveillance demonstrated that, in the
same market, approximately 40% of wild animal traders
and 20% of animal slaughterers had antibodies to SARS-
CoV or SARS-CoV–like animal virus, but none of them
had had SARS-like symptoms in the past 6 months. These
investigations raised questions about whether the presence
of the animal SARS-CoV–like virus in the market was an
isolated event or if this virus had been prevalent in the
human population in southern China before the SARS out-
break. A retrospective serologic study was conducted to
address these questions.
The Study
Serum samples collected in May 2001 from 938 healthy
Chinese adults in Hong Kong and 48 confirmed SARS
patients diagnosed in February and March 2003 in
Guangdong were studied. All serum samples were aliquot-
ed and stored at −20°C. The healthy adults were totally
asymptomatic persons randomly recruited after a tele-
phone interview concerning hepatitis B virus. The signs
and symptoms of the SARS patients met the World Health
Organization’s definition for surveillance, and SARS-CoV
infection had been confirmed virologically. 
All serum samples were heated at 56°C for 30 minutes.
Specific antibodies for SARS-CoV and SARS-CoV–like
virus were tested by using immunofluorescence (IF) assay
at 1:10 dilution on FRhK-4 cells infected with either a
human SARS-CoV strain (GZ50) (5) or an animal SARS-
CoV–like virus (SZ16) (6), as reported (1). For sera posi-
tive for anti–SARS-CoV or anti–SARS-CoV–like virus,
the antibody titer was further determined by serial titration.
The IF-positive serum samples were serially diluted from
1:20 to 1:640 and then mixed with 100 50% tissue culture
infective dose (TCID)50 of the representative human or ani-
mal virus strains for a serum neutralization assay. After
incubation for 1 hour at 37°C, the mixture was inoculated
in triplicate onto 96-well plates of FRhK-4 cell cultures.
The results were determined after 3-day incubation at
37°C. 
Seventeen (1.8%) archived samples from healthy adults
showed IF antibodies against the human virus, animal
virus, or both (titer range 1:20 to 1:1,280) and were con-
firmed by serum neutralization assay. An additional six
samples were IF-antibody positive at a 1:10 dilution to
either animal or human viruses, but they were negative in
neutralization assay and were treated as negative. The pos-
itive rate was highest in the group ages 51 to 60 years and
appeared to be more prevalent in female (13/561, 2.3%)
than male patients (4/377, 1.1%) (Table). Of the 17
seropositive serum samples, 10 were from housewives,
retired, or unemployed persons; 6 were from clerks,
unskilled workers, or students; and one was from a profes-
sional (Table). Most of the seropositive persons (13/17)
had a higher IF or neutralization antibody titer to the ani-
mal virus than the human virus (Figure). By contrast, the
control group, comprising convalescent-phase sera from
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human SARS-CoV and animal SARS-CoV–like viruses,
but they invariably exhibited higher IF and neutralization
antibody levels against the human virus than the animal
virus (Figure). 
Conclusions
While the exposure history and symptoms of study
participants were unavailable for assessment, our results
suggest that a small portion of Hong Kong adults had
acquired a SARS-CoV–related virus infection at least 2
years before the 2003 SARS outbreak. Cross-reactivity of
the antibody to human SARS-CoV and the animal SARS-
CoV–like virus must have occurred, in view of the
marked similarity between the two viruses. Recently, we
reported that the very similar sequences differed only by
60 to 80 nt, including an additional 29 nt in the animal
virus (6). We speculate that the viruses that affected the 17
healthy persons >2 years ago were antigenically closer to
the recently isolated animal SARS-CoV–like virus than
human SARS-CoV, but interspecies transmission from
animal to human was probably inefficient as the viruses
might not have adapted in the new host. This hypothesis
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Table. Distribution of age, gender, and occupation of SARS-CoV–seropositive adults recruited in 2001  
Age (y) 
No. of  
positive/total (%) 
No. of positive/total  
in males (%) 
No. of positive/total 
 in females (%) 
Occupation  
groups
b 
No. of  
positive/total (%) 
17–30  2/162 (1.2)  0/73 (0)  2/89 (2.2)  1  10/367 (2.7) 
31–40  3/236 (1.3)  0/93 (0)  3/143 (2.1)  2  5/235 (2.1) 
41–50  6/283 (2.1)  1/100 (1.0)  5/183 (2.7)  3  2/221 (0.9) 
51–60  4/150 (2.7)  3/57 (5.3)  1/93 (1.1)  4  0/110 (0) 
>60  2/107 (1.9)  0/55 (0)  2/52 (3.8)  5  0/5 (0) 
Total  17/938 (1.8)  4/378 (1.1)  13/560 (2.3)    17/938 (1.8) 
aSARS-CoV, severe acute respiratory syndrome–associated coronavirus. 
bGroup 1: Housewives (235), retired persons (96), and unemployed persons (36); Group 2: clerks (141), students (40), and associate professionals (54); group 3: service 
workers (47), craft-related workers (41), machine operators (56), and unskilled workers (77); group 4: managers and administrators professionals (33), professionals (35), 
civil servants (9), and sales persons (33); group 5: undefined. 
Figure. Correlation between antibodies against human severe acute respiratory syndrome cornonavirus (SARS-CoV) (anti-Hu SARS-
CoV) and animal (anti-An) SARS-CoV–like virus in seropositive healthy adults recruited in 2001 (dotted line) and in patients with SARS
in 2003 (thick line) by an immunofluorescence (A) and a neutralization (B) assay; and between neutralizing (NT) and immunofluores-
cence (IF) antibodies against Hu SARS-CoV (C) and a SARS-CoV–like virus (D).would explain why only a few persons became infected
and why they were likely to be asymptomatic. Avian
influenza is another example of a virus appearing first in
animals before causing a human disease. While approxi-
mately 3%–10% of healthy persons who were in close
contact with farm or market chicken or fowls showed pos-
itive antibody to avian influenza viruses at the time of the
H5N1 outbreak in humans in 1997, none of them had
symptoms of influenza (7).
Although human SARS-CoV and animal SARS-
CoV–like viruses are related to the three families of coro-
naviruses that cause respiratory and gastrointestinal dis-
eases in animals, phylogenetic analysis has shown that
they are different enough to make up their own, fourth
group. The number of members in this new group is not
clear. Important factors in the emergence of novel infec-
tious diseases from animal sources include extensive expo-
sure and rapid virus evolution (8), which facilitate human-
to-human transmission. The growth of the demand for
wildlife in markets in Guangdong in the past 15 years has
provided an ideal platform to facilitate interspecies virus
transmission from animals to humans. Such factors could
even directly trigger a zoonotic disease outbreak. Our
observations distinguished two distinct serologic patterns.
The high ratio of antibodies to the animal virus compared
to the relatively low ratio of antibodies to the human virus
in a small proportion of healthy adults >2 years ago signi-
fies the circulation of a SARS-CoV–like virus and its inef-
fective propagation in the human population. Following
rapid virus evolution and in the presence of an unknown
trigger, the novel SARS-CoV may have effectively adapt-
ed to the human host, as illustrated by a second pattern
characterized by a higher human-to-animal virus antibody
titer in infected persons. Although this pilot study was lim-
ited by an unstandardized design of sample collection, our
preliminary findings suggest that the occurrence of SARS
might not be due to an isolated cross-species transmission
event, but rather to the rapid evolution of a related virus
that has taken root in the human population. This implies
an expected pattern of potential SARS recurrence.
Measuring the prevalence of the two antibodies in differ-
ent species of animals and persons who had close contact
with the animals is important to improve our understand-
ing of SARS-CoV transmission dynamics. 
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